Clozapine vs Ziprasidone
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Schizophrenia
Shared mechanism: Dopamine D2 and serotonin 5-HT2A receptors (antagonist) · full Schizophrenia pipeline
Clozapine
Marketed by HLS Therapeutics Inc.
NCT00250575 · Phase 3 · completed
The study was open-label, single-arm, and had no placebo or active comparator; all 43 participants received clozapine. Its primary measures focused on hematological tests, blood-related adverse events, and monitoring-system compliance rather than a clinical symptom endpoint, and no results are posted.
Next expected readout: April 2027 · NCT04580134 (registry estimate)
Reported efficacy
Treatment efficacy rate (baseline,0.5 months,1 months, 2 months,4 months , 6 months , 8 months and 12 months); All-cause dropout rate (baseline,0.5 months,1 months, 2 months,4 months , 6 months , 8 months and 12 months): Primary 1, symptomatic response (40% or more PANSS total reduction) in phase 2 among 111 re-randomized nonresponders: clozapine 62.5% (20/32) vs amisulpride 44.7% (17/38) vs olanzapine 31.7% (13/41) (chi-square 6.9; P=.03), met. Primary 2, time to all-cause discontinuation: the paper reports no clear difference between treatment groups, missed. (mixed)
Result source: NCT03510325
Ziprasidone
Marketed by Viatris and partners
NCT00159770 · Phase 3 · completed
This 12-week, open-label, multicentre trial randomized 293 patients with chronic schizophrenia to ziprasidone (n=147) or to a comparator group of olanzapine, risperidone or quetiapine chosen by the investigator (n=146). The primary endpoint was total PANSS score, tested for non-inferiority with a margin of 7 points to the disadvantage of ziprasidone. Ziprasidone was non-inferior to the comparator group on total PANSS and on all subscores (P<0.0001), so the primary endpoint was met. The figures come from the peer-reviewed paper (Lublin et al., World J Biol Psychiatry 2009), whose abstract does not give a confidence interval.
Next expected readout: February 2027 · NCT03781115 (registry estimate)
Reported efficacy
Number of Events Recorded Based on Ziprasidone Side Effects Checklist During Randomized Trial (From Baseline up to Week 8); Change From Baseline in Simpson Angus Scale for Extrapyramidal Symptoms (SAS) (Baseline, Week 2, Week 4, Week 6, Week 8); Change From Baseline in the Barnes Akathisia Scale (BAS) (Baseline, Week 2, Week 4, Week 6, Week 8); Number of Participants With High and Low Levels in Serum Prolactin Concentration (Baseline, Week 8); Vital Signs: Systolic and Diastolic Blood Pressure Levels (Baseline, Week 1, Week 2, Week 4, Week 6, Week 8); Electrocardiogram (EKG): Number of Participants With an Increase From Baseline to Corrected QT (QTc) Interval >/= 500 Milliseconds (Msec) (6 hours after dosing of Weeks 1, 2 and 8); Change From Baseline in Positive and Negative Syndrome Scale (PANSS) Total Score (Baseline, Week 2, Week 4, Week 6, Week 8); Percentage of Participants With Response (Baseline, Week 2, Week 4, Week 6, Week 8); Change From Baseline in Abnormal Involuntary Movement Scale (AIMS) Score (Baseline, Week 2, Week 4, Week 6, Week 8); Number of Treatment-emergent Adverse Events During Randomized Trial (From Baseline up to Week 8): Change from baseline in PANSS total score at Week 8, high-dose ziprasidone (320 mg/day) vs standard dose (160 mg/day plus placebo capsules): -8.62 vs -5.48, mixed-model difference -1.37 (95% CI -7.20 to 4.45), p=0.642. No registered primary favoured the high dose; the Simpson-Angus extrapyramidal score was worse on the high dose at Week 2 (difference 1.02, 95% CI 0.08 to 1.95, p=0.033). (missed)
Result source: NCT00403546
Results for Schizophrenia
Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.
These assets measured different things. Their trials share no endpoint in common, so no efficacy row can be built. That is a property of the programmes rather than a gap in the record: each asset's own reported endpoints are listed below.
| Key endpoint | Clozapine | Ziprasidone |
|---|---|---|
| PANSS total, change | —Not posted · NCT00649844 | —Not posted · NCT00159770 |
| CGI-S, change | —Not posted · NCT00649844 | -1.2 vs -1.2vs HaloperidolNCT00723606 |
| PANSS response | —Not posted · NCT00649844 | —Not posted · NCT00159770 |
| PSP, change | —Not posted · NCT00649844 | —Not posted · NCT00159770 |
| Relapse (% of patients) | —Not posted · NCT00649844 | —Not posted · NCT00159770 |
PANSS total, change
- Clozapine
- —Not posted · NCT00649844
- Ziprasidone
- —Not posted · NCT00159770
CGI-S, change
- Clozapine
- —Not posted · NCT00649844
- Ziprasidone
- -1.2 vs -1.2vs HaloperidolNCT00723606
PANSS response
- Clozapine
- —Not posted · NCT00649844
- Ziprasidone
- —Not posted · NCT00159770
PSP, change
- Clozapine
- —Not posted · NCT00649844
- Ziprasidone
- —Not posted · NCT00159770
Relapse (% of patients)
- Clozapine
- —Not posted · NCT00649844
- Ziprasidone
- —Not posted · NCT00159770
- Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
- An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.
Only safety results can currently be compared in this indication. Reviewed efficacy summaries, where available, are listed separately.
safety
Coverage. Clozapine: 3 of 4 rows · Ziprasidone: 4 of 4 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.
| Reported metric | Clozapine | Ziprasidone |
|---|---|---|
| Dropout rate | 41.7%a NCT01639872 · Phase 4 · registry result, not featured evidence show 2 more results0% NCT00498550 · Phase 4 · registry result, not featured evidence 17.2% NCT02404155 · Phase na · registry result, not featured evidence | —High doseb NCT00403546 · Phase 3 · combination · Schizophrenia · phase 3 show 9 more results—High dose NCT00403546 · Phase 3 · combination · Schizophrenia · phase 3 26.8% NCT00338949 · Phase 4 · registry result, not featured evidence 58.5% NCT00406315 · Phase 4 · registry result, not featured evidence 12.5% NCT00351000 · Phase 4 · registry result, not featured evidence 2.1% NCT00723606 · Phase 3 · registry result, not featured evidence 99.1% NCT00139737 · Phase 3 · registry result, not featured evidence 88.4% NCT00174447 · Phase 3 · registry result, not featured evidence 35.7% NCT00538642 · Phase na · registry result, not featured evidence 0% NCT00225498 · Phase na · registry result, not featured evidence |
| Discontinued due to AEs | —a NCT01639872 · Phase 4 · registry result, not featured evidence show 2 more results— NCT00498550 · Phase 4 · registry result, not featured evidence — NCT02404155 · Phase na · registry result, not featured evidence | —High doseb NCT00403546 · Phase 3 · combination · Schizophrenia · phase 3 show 9 more results—High dose NCT00403546 · Phase 3 · combination · Schizophrenia · phase 3 — NCT00338949 · Phase 4 · registry result, not featured evidence 16.2% NCT00406315 · Phase 4 · registry result, not featured evidence — NCT00351000 · Phase 4 · registry result, not featured evidence 1.1% NCT00723606 · Phase 3 · registry result, not featured evidence 16.9% NCT00139737 · Phase 3 · registry result, not featured evidence 44.2% NCT00174447 · Phase 3 · registry result, not featured evidence — NCT00538642 · Phase na · registry result, not featured evidence — NCT00225498 · Phase na · registry result, not featured evidence |
| Serious AEs | 13%a NCT01639872 · Phase 4 · registry result, not featured evidence show 2 more results26.7% NCT00498550 · Phase 4 · registry result, not featured evidence 6.9% NCT02404155 · Phase na · registry result, not featured evidence | —High doseb NCT00403546 · Phase 3 · combination · Schizophrenia · phase 3 show 9 more results10.5%High dose NCT00403546 · Phase 3 · combination · Schizophrenia · phase 3 6.7% NCT00338949 · Phase 4 · registry result, not featured evidence 9.1% NCT00406315 · Phase 4 · registry result, not featured evidence 0% NCT00351000 · Phase 4 · registry result, not featured evidence 0% NCT00723606 · Phase 3 · registry result, not featured evidence 9.7% NCT00139737 · Phase 3 · registry result, not featured evidence 30.2% NCT00174447 · Phase 3 · registry result, not featured evidence 0% NCT00538642 · Phase na · registry result, not featured evidence 0% NCT00225498 · Phase na · registry result, not featured evidence |
| Most frequent reported AEs | a other-sialorrhea 43.5% weight gain 30.4% sedation 21.7% NCT01639872 · Phase 4 · registry result, not featured evidence show 2 more resultsgastrointestinal disorder - other: hypersalivation 66.7% somnolence 60% weight gain 40% NCT00498550 · Phase 4 · registry result, not featured evidence salivation 68.2% sedation 52.9% malaise 52.6% NCT02404155 · Phase na · registry result, not featured evidence | High doseb hypertension 18.4% somnolence 15.8% headache 10.5% NCT00403546 · Phase 3 · combination · Schizophrenia · phase 3 show 6 more resultsinsomnia 19.1% somnolence 14.5% nausea 11.6% NCT00406315 · Phase 4 · registry result, not featured evidence difficulty breathing 4.2% dizziness 4.2% NCT00351000 · Phase 4 · registry result, not featured evidence dizziness 3.7% somnolence 3.7% akathisia 3.2% NCT00723606 · Phase 3 · registry result, not featured evidence electrocardiogram qt prolonged 13.9% insomnia 6.3% anxiety 4.5% NCT00139737 · Phase 3 · registry result, not featured evidence anxiety 23.3% insomnia 16.3% schizophrenia 14% NCT00174447 · Phase 3 · registry result, not featured evidence |
Notes
- aPopulation comparability has not been reviewed for these studies.
- bPopulation comparability has not been reviewed for 8 of these studies.
Reported by one asset only
Endpoints only one of the selected assets measured, so there is nothing to compare them against.
Clozapine
Ziprasidone
show 3 more results
show 3 more results
show 1 more result
show 1 more result
show 2 more results
+ 21 further endpoints in the CSV export.
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Clozapine's landscape · Ziprasidone's landscape